MADISON, WI, May 16, 2022 – Cellular Logistics, a Madison, Wisconsin company that is creating a new way to restore heart function and help patients with heart damage is launching a new financing round to advance its product, Tandem™, to the next stage of product development, and moving...
MADISON, WI, May 10, 2022 – Cellular Logistics, a Madison-area company that is creating a new way to restore heart function and help patients with heart damage has been chosen to present at the Midwest Growth Capital Symposium (MGCS) being held on May 17-18, 2022. 2022...
Cellular Logistics Receives Commercialization Funding...
MADISON, WI, November 23, 2021 – Cellular Logistics, a Madison-area company that is creating a new way to restore heart function and help patients with heart damage announces promising early data using its Tandem™ biomatrix technology. Investigators at the University of Wisconsin-Madison, led by Drs....
Cellular Logistics Selected to Pitch at the Wisconsin Early Stage Symposium...
Early-stage biotech startups find common ground at Forward BIOLABS...
Cellular Logistics Adds to Scientific Advisory Board MADISON, Wis., July 20, 2021 – Cellular Logistics, a Madison-area company that hopes to create new ways to restore heart function and help patients with heart damage, has appointed Philippe Marchand as a new member of their Scientific Advisory Board (SAB). Mr. Marchand, a...
Dr. Eric Schmuck & Cellular Logistics Awarded SEED Grant ...
MADISON, Wis., June 8, 2021 – Cellular Logistics has joined Forward BIOLABS, a non-profit, co-working life science lab for an early-stage biotech. Forward BIOLABS life science laboratories are fully equipped, maintained, supported, and come with introductions, training, and networking that help startups grow. It was founded...
MADISON, Wis., March 09, 2021 – Cellular Logistics has been awarded a $321,000 SBIR grant from the National Institutes of Health to optimize an induced pluripotent stem cell-derived cardiac fibroblast (iPSC-CF) technology to assemble Tandem™ HF biomaterial to facilitate heart failure treatment. The aim of this grant is to develop a second manufacturing pipeline of cardiac fibroblasts to manufacture Cellular Logistics’ novel Tandem™ HF biomaterial. iPSC-CF has the potential to offer a new predictable, renewable, and...
